ADVERTISEMENT

Pricing Strategies

‘The Right Call:’ Australia’s PBAC Addresses ‘Unprecedented’ Backlog With Extra Meeting

‘The Right Call:’ Australia’s PBAC Addresses ‘Unprecedented’ Backlog With Extra Meeting

The government’s decision for the Pharmaceutical Benefits Advisory Committee to hold an extra meeting in 2025 has been welcomed by Medicines Australia, which says that Australians already wait on average 466 days from the time a medicine is approved to when it is subsidized.

Australian Industry Strikes Deal On Deferred PBS Submissions, Challenges Govt's Capacity Claim

Australian Industry Strikes Deal On Deferred PBS Submissions, Challenges Govt's Capacity Claim

Medicines Australia has expressed skepticism over the Pharmaceutical Benefits Advisory Committee’s claim that in March 2025 it will only be able to assess 32 submissions from companies that want to get their drugs subsidized under the Pharmaceutical Benefits Scheme.

Big Pharma Faces A Big Reality Check In Cell And Gene Therapy

Big Pharma Faces A Big Reality Check In Cell And Gene Therapy

Big pharma executives at ARM’s Cell and Gene Meeting on the Mesa shared some of the practical challenges of bringing one-time treatments to market in hemophilia, cancer and beyond.

New Pharma Research Law Fails To Make Germany More Competitive Says EUCOPE Head

New Pharma Research Law Fails To Make Germany More Competitive Says EUCOPE Head

Germany’s Medical Research Act clears its final legal hurdle after federal council sign off.

Perspectives From The Front Lines: Navigating The First Round Of Medicare Price Negotiation

Perspectives From The Front Lines: Navigating The First Round Of Medicare Price Negotiation

Policy experts and consultants recount their experiences shepherding manufacturers through the first round of Medicare price negotiations during a recent webinar.

Changing Chinese Market Dynamics Hit Merck Where It Hurts

Changing Chinese Market Dynamics Hit Merck Where It Hurts

China gets more complicated as multinational drug makers venture deep into it. Even with a local savvy business partner, Merck is learning to navigate through fast-shifting market dynamics amid policy changes, consumer perceptions of foreign brands, and competition from local firms as it takes stock of its market access, pricing and life cycle management strategies.

Telmisartan Leads UK Rises In September As Price Surges Subside

Telmisartan Leads UK Rises In September As Price Surges Subside

September saw the extreme price rises of the last few months subside in the UK, albeit still seeing a handful of treble-digit percentage average increases for products like telmisartan.

Perspectives From The Front Lines: Navigating The First Round Of Medicare Price Negotiation

Perspectives From The Front Lines: Navigating The First Round Of Medicare Price Negotiation

Policy experts and consultants recount their experiences shepherding manufacturers through the first round of Medicare price negotiations during a recent webinar.

Humira Pricing Takes Center Stage In Dutch Courts

Humira Pricing Takes Center Stage In Dutch Courts

A public interest group has accused the pharma major of using excessive pricing to bolster sales of blockbuster Humira, consequently damaging the health of Dutch patients. 

Sanders Mulls Generic Possibilities As He Blasts Novo Over High Ozempic And Wegovy Prices

Sanders Mulls Generic Possibilities As He Blasts Novo Over High Ozempic And Wegovy Prices

In a closely anticipated US Senate Committee hearing, Novo’s CEO was grilled by US senator Bernie Sanders and others on the high price of Ozempic and Wegovy in the country.